Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 04 2024 - 8:30AM
Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative
biopharmaceutical company focused on acquiring and advancing assets
to enhance long-term value for shareholders through product
revenue, equity holdings and dividend and royalty revenue, today
announced that Lindsay A. Rosenwald, M.D., Chairman, President and
Chief Executive Officer, will present a corporate overview at the
H.C. Wainwright 26th Annual Global Investment Conference. The
presentation will be available for on-demand viewing by conference
attendees starting on September 9, 2024, at 7:00 a.m. ET. The
Company will also attend one-on-one meetings during the conference.
About Fortress BiotechFortress
Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical
company focused on acquiring and advancing assets to enhance
long-term value for shareholders through product revenue, equity
holdings and dividend and royalty revenue. The company has seven
marketed prescription pharmaceutical products and over 20 programs
in development at Fortress, at its majority-owned and
majority-controlled partners and subsidiaries and at partners and
subsidiaries it founded and in which it holds significant minority
ownership positions. Such product candidates span six large-market
areas, including oncology, rare diseases and gene therapy, which
allow it to create value for shareholders. Fortress advances its
diversified pipeline through a streamlined operating structure that
fosters efficient drug development. The Fortress model is focused
on leveraging its significant biopharmaceutical industry expertise
and network to further expand the company’s portfolio of product
opportunities. Fortress has established partnerships with some of
the world’s leading academic research institutions and
biopharmaceutical companies to maximize each opportunity to its
full potential, including AstraZeneca, City of Hope, Fred
Hutchinson Cancer Center, Nationwide Children’s Hospital and
Sentynl. For more information, visit www.fortressbiotech.com.
Company Contact:Jaclyn
JaffeFortress Biotech, Inc.(781) 652-4500ir@fortressbiotech.com
Media Relations Contact:Tony
Plohoros6 Degrees(908) 591-2839tplohoros@6degreespr.com
Fortress Biotech (NASDAQ:FBIOP)
Historical Stock Chart
From Oct 2024 to Nov 2024
Fortress Biotech (NASDAQ:FBIOP)
Historical Stock Chart
From Nov 2023 to Nov 2024